Signatures of mutation and selection in the cancer genc

Nature

463, 893-898

DOI: 10.1038/nature08768

Citation Report

#	Article	IF	Citations
1	Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis. Current Genomics, 2010, 11, 297-310.	0.7	15
2	Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cellular and Molecular Life Sciences, 2010, 67, 3467-3488.	2.4	44
3	Passenger mutations as a marker of clonal cell lineages in emerging neoplasia. Seminars in Cancer Biology, 2010, 20, 294-303.	4.3	27
4	Characterization of FRA7B, a human common fragile site mapped at the 7p chromosome terminal region. Cancer Genetics and Cytogenetics, 2010, 202, 47-52.	1.0	31
5	The â€˜omicsâ€™ of cancer. Cancer Genetics and Cytogenetics, 2010, 203, 37-42.	1.0	3
6	CAM: A web tool for combining array CGH and microarray gene expression data from multiple samples. Computers in Biology and Medicine, 2010, 40, 781-785.	3.9	2
7	Merotelic attachments and non-homologous end joining are the basis of chromosomal instability. Cell Division, 2010, 5, 13.	1.1	24
8	History of leukemia-lymphoma cell lines. Human Cell, 2010, 23, 75-82.	1.2	33
9	Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer, 2010, 102, 1555-1577.	2.9	1,167
10	ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines. British Journal of Cancer, 2010, 103, 715-726.	2.9	124
11	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467, 1114-1117.	13.7	2,184
12	How accurate are cancer cell lines?. Nature, 2010, 463, 858-858.	13.7	60
13	Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics, 2010, 11, 685-696.	7.7	1,014
14	Fractal-like Distributions over the Rational Numbers in High-throughput Biological and Clinical Data. Nature Precedings, 2010, , .	0.1	0
16	Analysis of next-generation genomic data in cancer: accomplishments and challenges. Human Molecular Genetics, 2010, 19, R188-R196.	1.4	122
17	The Use of DNA Transposons for Cancer Gene Discovery in Mice. Methods in Enzymology, 2010, 477, 91-106.	0.4	1
18	Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14639-14644.	3.3	320
19	PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15145-15150.	3.3	202

#	Article	IF	Citations
20	Mutagenesis as a Genetic Research Strategy. Genetics, 2010, 185, 1135-1139.	1.2	9
21	Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. Journal of Experimental Medicine, 2010, 207, 2581-2594.	4.2	58
22	Are aneuploidy and chromosome breakage caused by a CINgle mechanism?. Cell Cycle, 2010, 9, 2275-2280.	1.3	22
23	Epigenetic regulation of theINK4b-ARF-INK4alocus. Epigenetics, 2010, 5, 685-690.	1.3	211
26	Epigenetic Alterations as Cancer Diagnostic, Prognostic, and Predictive Biomarkers. Advances in Genetics, 2010, 71, 125-176.	0.8	85
27	Induction of Human Epithelial Stem/Progenitor Expansion by FOXM1. Cancer Research, 2010, 70, 9515-9526.	0.4	92
28	Germline copy number variation and cancer risk. Current Opinion in Genetics and Development, 2010, 20, 282-289.	1.5	115
29	Synthetic lethal approaches to breast cancer therapy. Nature Reviews Clinical Oncology, 2010, 7, 718-724.	12.5	86
30	Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. Genome Biology, 2010, 11, R114.	13.9	35
31	Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biology, 2010, 11, R100.	13.9	24
32	A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biology, 2010, 11, R92.	3.8	125
33	Mutant proteins as cancer-specific biomarkers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2444-2449.	3.3	157
34	Drosophila Duplication Hotspots Are Associated with Late-Replicating Regions of the Genome. PLoS Genetics, 2011, 7, e1002340.	1.5	31
35	A continuum model for tumour suppression. Nature, 2011, 476, 163-169.	13.7	432
36	Studies of genomic copy number changes in human cancers reveal signatures of DNA replication stress. Molecular Oncology, 2011, 5, 308-314.	2.1	69
37	Large-scale analysis of chromosomal aberrations in cancer karyotypes reveals two distinct paths to aneuploidy. Genome Biology, 2011, 12, R61.	13.9	49
38	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biology, 2011, 12, R41.	3.8	2,546
40	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	9.4	270

#	Article	IF	Citations
41	Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 2011, 144, 27-40.	13.5	2,020
42	Mutant onco-proteins as drug targets: successes, failures, and future prospects. Current Opinion in Genetics and Development, 2011, 21, 29-33.	1.5	10
43	Exploring the Genomes of Cancer Cells: Progress and Promise. Science, 2011, 331, 1553-1558.	6.0	606
44	Failure of Origin Activation in Response to Fork Stalling Leads to Chromosomal Instability at Fragile Sites. Molecular Cell, 2011, 43, 122-131.	4.5	157
45	Collisions between Replication and Transcription Complexes Cause Common Fragile Site Instability at the Longest Human Genes. Molecular Cell, 2011, 44, 966-977.	4.5	470
46	Non-genomic loss of PTEN function in cancer: not in my genes. Trends in Pharmacological Sciences, 2011, 32, 131-140.	4.0	137
47	SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts. New England Journal of Medicine, 2011, 365, 1384-1395.	13.9	1,094
48	Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Experimental and Therapeutic Medicine, 2011, 2, 457-463.	0.8	40
49	Accurate estimation of homologue-specific DNA concentration-ratios in cancer samples allows long-range haplotyping. Nature Precedings, 0, , .	0.1	15
51	Network-Guided Analysis of Genes with Altered Somatic Copy Number and Gene Expression Reveals Pathways Commonly Perturbed in Metastatic Melanoma. PLoS ONE, 2011, 6, e18369.	1.1	51
52	Pipeline for Large-Scale Microdroplet Bisulfite PCR-Based Sequencing Allows the Tracking of Hepitype Evolution in Tumors. PLoS ONE, 2011, 6, e21332.	1.1	8
53	MicroRNA Expression and Regulation in Human Ovarian Carcinoma Cells by Luteinizing Hormone. PLoS ONE, 2011, 6, e21730.	1.1	24
54	Fractal-like Distributions over the Rational Numbers in High-throughput Biological and Clinical Data. Scientific Reports, 2011, 1, 191.	1.6	16
55	A model for random genetic damage directing selection of diploid or aneuploid tumours. Cell Proliferation, 2011, 44, 212-223.	2.4	3
56	53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nature Cell Biology, 2011, 13, 243-253.	4.6	584
57	Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer, 2011, 11, 541-557.	12.8	364
58	NF-ÎºB addiction and its role in cancer: â€˜one size does not fit allâ€™. Oncogene, 2011, 30, 1615-1630.	2.6	419
59	The genomic complexity of primary human prostate cancer. Nature, 2011, 470, 214-220.	13.7	1,107

#	Article	IF	Citations
60	Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature, 2011, 470, 120-123.	13.7	377
61	Charting a course for genomic medicine from base pairs to bedside. Nature, 2011, 470, 204-213.	13.7	823
62	DNA fragility put into context. Nature, 2011, 470, 46-47.	13.7	5
63	When catastrophe strikes a cell. Nature, 2011, 470, 476-477.	13.7	77
64	Genomic instability in induced stem cells. Cell Death and Differentiation, 2011, 18, 745-753.	5.0	138
65	Phylomedicine: an evolutionary telescope to explore and diagnose the universe of disease mutations. Trends in Genetics, 2011, 27, 377-386.	2.9	74
66	Molecular Profiling of Cancerâ€"The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology, 2011, 38, 173-185.	0.8	61
67	A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells. Cancer Cell, 2011, 20, 620-634.	7.7	449
68	Centromere fission, not telomere erosion, triggers chromosomal instability in human carcinomas. Carcinogenesis, 2011, 32, 796-803.	1.3	40
69	What can exome sequencing do for you?. Journal of Medical Genetics, 2011, 48, 580-589.	1.5	321
70	Technology-specific error signatures in the 1000 Genomes Project data. Human Genetics, 2011, 130, 505-516.	1.8	37
71	Integrated genomics of ovarian xenograft tumor progression and chemotherapy response. BMC Cancer, 2011, 11, 308.	1.1	10
72	Genome-wide analysis of Ollier disease: Is it all in the genes?. Orphanet Journal of Rare Diseases, 2011, 6, 2.	1.2	36
73	Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes and Cancer, 2011, 50, 456-465.	1.5	107
74	Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. International Journal of Cancer, 2011, 129, 1848-1858.	2.3	41
75	The Essential Role of Evasion from Cell Death in Cancer. Advances in Cancer Research, 2011, 111, 39-96.	1.9	79
76	Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1128-36.	3.3	200
77	T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success. Journal of Investigative Dermatology, 2011, 131, 1806-1816.	0.3	38

#	Article	IF	Citations
78	Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor Î³2 Expression. Molecular and Cellular Biology, 2011, 31, 4270-4285.	1.1	63
79	Comparison of Constitutional and Replication Stress-Induced Genome Structural Variation by SNP Array and Mate-Pair Sequencing. Genetics, 2011, 187, 675-683.	1.2	20
80	Large duplications at reciprocal translocation breakpoints that might be the counterpart of large deletions and could arise from stalled replication bubbles. Genome Research, 2011, 21, 525-534.	2.4	32
81	Hydroxyurea induces de novo copy number variants in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17360-17365.	3.3	82
82	Losing balance: Hardyâ€“Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer. Human Molecular Genetics, 2011, 20, 4831-4839.	1.4	6
83	Prognostic Significance of p14ARF, p15INK4b, and p16INK4a Inactivation in Malignant Peripheral Nerve Sheath Tumors. Clinical Cancer Research, 2011, 17, 3771-3782.	3.2	53
84	Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Human Molecular Genetics, 2011, 20, 497-509.	1.4	56
85	Germline Fitness-Based Scoring of Cancer Mutations. Genetics, 2011, 188, 383-393.	1.2	15
86	VentX trans-Activates p53 and p16ink4a to Regulate Cellular Senescence. Journal of Biological Chemistry, 2011, 286, 12693-12701.	1.6	16
87	The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers. Human Molecular Genetics, 2011, 20, 1488-1501.	1.4	42
88	Molecular profiling of common fragile sites in human fibroblasts. Nature Structural and Molecular Biology, 2011, 18, 1421-1423.	3.6	112
89	Transcription factor Dlx2 protects from TGFÎ²-induced cell-cycle arrest and apoptosis. EMBO Journal, 2011, 30, 4489-4499.	3.5	56
90	Mechanisms of telomere loss and their consequences for chromosome instability. Frontiers in Oncology, 2012, 2, 135.	1.3	98
91	Chromosome Fragile Sites in Arabidopsis Harbor Matrix Attachment Regions That May Be Associated with Ancestral Chromosome Rearrangement Events. PLoS Genetics, 2012, 8, e1003136.	1.5	10
92	Initiation of Genome Instability and Preneoplastic Processes through Loss of Fhit Expression. PLoS Genetics, 2012, 8, e1003077.	1.5	84
93	A Single-Nucleotide Substitution Mutator Phenotype Revealed by Exome Sequencing of Human Colon Adenomas. Cancer Research, 2012, 72, 6279-6289.	0.4	61
94	Linking stem cells to chromosomal instability. OncoImmunology, 2012, 1, 195-200.	2.1	2
95	Haploinsufficient Gene Selection in Cancer. Science, 2012, 337, 47-48.	6.0	12

#	Article	IF	Citations
96	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.4	100
97	ABSOLUTE cancer genomics. Nature Biotechnology, 2012, 30, 620-621.	9.4	17
98	Splice variant PRKC-Î¶-PrC is a novel biomarker of human prostate cancer. British Journal of Cancer, 2012, 107, 388-399.	2.9	12
99	Statistical model-based testing to evaluate the recurrence of genomic aberrations. Bioinformatics, 2012, 28, i115-i120.	1.8	12
100	Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis. Cancer Research, 2012, 72, 4383-4393.	0.4	242
101	Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E252-9.	3.3	192
102	The Role of Fragile Sites in Sporadic Papillary Thyroid Carcinoma. Journal of Thyroid Research, 2012, 2012, 1-12.	0.5	8
103	Emerging frontiers in pancreatic cancer research. Current Opinion in Gastroenterology, 2012, 28, 516-522.	1.0	13
104	Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures: Figure 1. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 156-160.	2.2	26
105	The expanding role of epigenetics. Global Cardiology Science & Practice, 2012, 2012, 7.	0.3	12
106	Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood, 2012, 120, 4191-4196.	0.6	292
107	Cancer in Light of Experimental Evolution. Current Biology, 2012, 22, R762-R771.	1.8	103
108	Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochemical Journal, 2012, 441, 523-540.	1.7	1,243
109	Common Fragile Sites: Genomic Hotspots of DNA Damage and Carcinogenesis. International Journal of Molecular Sciences, 2012, 13, 11974-11999.	1.8	60
110	Genetic heterogeneity and cancer drug resistance. Lancet Oncology, The, 2012, 13, e178-e185.	5.1	386
111	A Mouse Model of Rhabdomyosarcoma Originating from the Adipocyte Lineage. Cancer Cell, 2012, 22, 536-546.	7.7	109
112	Replication fork dynamics and the DNA damage response. Biochemical Journal, 2012, 443, 13-26.	1.7	112
113	Localization of centromeric breaks in head and neck squamous cell carcinoma. Cancer Genetics, 2012, 205, 622-629.	0.2	6

#	Article	IF	Citations
114	Estimation of rearrangement phylogeny for cancer genomes. Genome Research, 2012, 22, 346-361.	2.4	108
115	Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene, 2012, 31, 3939-3948.	2.6	87
116	Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respiratory Medicine, 2012, 106, 173-183.	1.3	67
117	Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential. Science, 2012, 337, 104-109.	6.0	172
118	Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 2012, 485, 502-506.	13.7	671
119	Passenger deletions generate therapeutic vulnerabilities in cancer. Nature, 2012, 488, 337-342.	13.7	294
120	Replication stress and mechanisms of CNV formation. Current Opinion in Genetics and Development, 2012, 22, 204-210.	1.5	91
121	Screens, maps & networks: from genome sequences to personalized medicine. Current Opinion in Genetics and Development, 2012, 22, 36-44.	1.5	15
122	Evolution of the cancer genome. Nature Reviews Genetics, 2012, 13, 795-806.	7.7	532
123	The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 77-87.	8.2	91
124	A TRF1-controlled common fragile site containing interstitial telomeric sequences. Chromosoma, 2012, 121, 465-474.	1.0	46
125	Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families. Genes Chromosomes and Cancer, 2012, 51, 1109-1113.	1.5	7
126	Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. BMC Genomics, 2012, 13, 719.	1.2	32
127	Preliminary evidence of different selection pressures on cancer cells as compared to normal tissues. Theoretical Biology and Medical Modelling, 2012, 9, 44.	2.1	13
128	Structural mutations in cancer: mechanistic and functional insights. Trends in Genetics, 2012, 28, 550-559.	2.9	67
129	What history tells us XXVIII. What is really new in the current evolutionary theory of cancer?. Journal of Biosciences, 2012, 37, 609-612.	0.5	7
130	Neurofibromatosis Type 1. , 2012, , .		23
131	Developing Algorithms to Discover Novel Cancer Genes: A look at the challenges and approaches. IEEE Signal Processing Magazine, 2012, 29, 89-97.	4.6	7

#	Article	IF	Citations
132	Rapid Visualisation of Microarray Copy Number Data for the Detection of Structural Variations Linked to a Disease Phenotype. PLoS ONE, 2012, 7, e43466.	1.1	1
133	IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. Journal of Ovarian Research, 2012, 5, 3.	1.3	23
134	A wholeâ€genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptorâ€negative and â€positive breast cancers. Journal of Pathology, 2012, 227, 29-41.	2.1	58
135	An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics, 2012, 12, 1319-1327.	1.3	22
136	High Prevalence of Evolutionarily Conserved and Species-Specific Genomic Aberrations in Mouse Pluripotent Stem Cells. Stem Cells, 2012, 30, 612-622.	1.4	48
137	Genome-wide copy number analysis of single cells. Nature Protocols, 2012, 7, 1024-1041.	5.5	332
138	Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, 2012, 149, 979-993.	13.5	1,673
139	The Life History of 21 Breast Cancers. Cell, 2012, 149, 994-1007.	13.5	1,249
140	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486, 346-352.	13.7	4,708
141	DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Molecular Medicine, 2012, 4, 743-760.	3.3	92
142	Clonal evolution in cancer. Nature, 2012, 481, 306-313.	13.7	2,570
143	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106
144	Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. Annual Review of Genomics and Human Genetics, 2012, 13, 171-205.	2.5	86
145	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486, 395-399.	13.7	1,778
146	A tumour suppressor network relying on the polyamineâ€“hypusine axis. Nature, 2012, 487, 244-248.	13.7	133
147	Condensin dysfunction in human cells induces nonrandom chromosomal breaks in anaphase, with distinct patterns for both unique and repeated genomic regions. Chromosoma, 2012, 121, 191-199.	1.0	24
148	Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats. Human Genetics, 2012, 131, 1345-1359.	1.8	16
149	Mutational profiling of sporadic versus toxin-associated brain cancer formation: Initial findings using loss of heterozygosity profiling. International Journal of Hygiene and Environmental Health, 2012, 215, 427-433.	2.1	3

#	Article	IF	Citations
150	Common fragile sites: mechanisms of instability revisited. Trends in Genetics, 2012, 28, 22-32.	2.9	219
151	Evolution of the cancer genome. Trends in Genetics, 2012, 28, 155-163.	2.9	127
152	The complex basis underlying common fragile site instability in cancer. Trends in Genetics, 2012, 28, 295-302.	2.9	72
153	Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. Journal of Ovarian Research, 2012, 5, 4.	1.3	19
154	Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts. Genes Chromosomes and Cancer, 2012, 51, 272-282.	1.5	13
155	Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Human Mutation, 2012, 33, 763-776.	1.1	44
156	Next generation sequencing and a new era of medicine. Gut, 2013, 62, 920-932.	6.1	24
157	In vitro threeâ€dimensional (3D) models in cancer research: An update. Molecular Carcinogenesis, 2013, 52, 167-182.	1.3	276
158	Posttranslational modifications regulate HIPK2, a driver of proliferative diseases. Journal of Molecular Medicine, 2013, 91, 1051-1058.	1.7	38
159	53BP1 Alters the Landscape of DNA Rearrangements and Suppresses AID-Induced B Cell Lymphoma. Molecular Cell, 2013, 49, 623-631.	4.5	33
160	Common chromosomal fragile site FRA16D tumor suppressor WWOX gene expression and metabolic reprograming in cells. Genes Chromosomes and Cancer, 2013, 52, 823-831.	1.5	27
161	Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer. Cancer Letters, 2013, 336, 85-95.	3.2	10
162	Discovery and analysis of consistent active sub-networks in cancers. BMC Bioinformatics, 2013, 14, S7.	1.2	12
163	Array Comparative Genomic Hybridization. Methods in Molecular Biology, 2013, , .	0.4	1
164	Large chromosome deletions, duplications, and gene conversion events accumulate with age in normal human colon crypts. Aging Cell, 2013, 12, 269-279.	3.0	31
165	Common Fragile Site Profiling in Epithelial and Erythroid Cells Reveals that Most Recurrent Cancer Deletions Lie in Fragile Sites Hosting Large Genes. Cell Reports, 2013, 4, 420-428.	2.9	166
166	Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. Journal of Pathology, 2013, 230, 261-269.	2.1	180
167	Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes. Biochemical Journal, 2013, 449, 581-594.	1.7	172

#	Article	IF	Citations
168	Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cellular Signalling, 2013, 25, 1086-1095.	1.7	180
169	The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large Bâ€cell lymphoma. Genes Chromosomes and Cancer, 2013, 52, 764-774.	1.5	34
170	The Human Specialized DNA Polymerases and Non-B DNA: Vital Relationships to Preserve Genome Integrity. Journal of Molecular Biology, 2013, 425, 4767-4781.	2.0	51
171	Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome. Cell, 2013, 155, 948-962.	13.5	695
172	DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nature Communications, 2013, 4, 1502.	5.8	100
173	Micro and Nano Flow Systems for Bioanalysis. , 2013, , .		3
174	Pan-cancer patterns of somatic copy number alteration. Nature Genetics, 2013, 45, 1134-1140.	9.4	1,616
175	Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes and Development, 2013, 27, 2513-2530.	2.7	220
176	The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501, 338-345.	13.7	1,969
177	Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. Clinical Epigenetics, 2013, 5, .	1.8	0
178	The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. BMC Cancer, 2013, 13, 593.	1.1	48
179	Exploiting FOXM1â€orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosis. International Journal of Cancer, 2013, 132, 2095-2106.	2.3	31
180	Research in Computational Molecular Biology. Lecture Notes in Computer Science, 2013, , .	1.0	17
181	Signature discovery for personalized medicine. , 2013, , .		1
182	Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Research, 2013, 23, 217-227.	2.4	139
183	MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis, 2013, 34, 454-463.	1.3	181
184	Identification of Early Replicating Fragile Sites that Contribute to Genome Instability. Cell, 2013, 152, 620-632.	13.5	364
185	Comprehensive genome characterization of solitary fibrous tumors using highâ€resolution arrayâ€based comparative genomic hybridization. Genes Chromosomes and Cancer, 2013, 52, 156-164.	1.5	6

#	Article	IF	Citations
186	Affinityâ€based microarrays for proteomic analysis of cancer tissues. Proteomics - Clinical Applications, 2013, 7, 8-15.	0.8	32
187	Mechanism of Replicative DNA Polymerase Delta Pausing and a Potential Role for DNA Polymerase Kappa in Common Fragile Site Replication. Journal of Molecular Biology, 2013, 425, 232-243.	2.0	54
188	Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines. Cancer Genetics, 2013, 206, 191-205.	0.2	23
189	Cancer stem cells as â€˜units of selectionâ€™. Evolutionary Applications, 2013, 6, 102-108.	1.5	66
190	Distinguishing Somatic and Germline Copy Number Events in Cancer Patient DNA Hybridized to Whole-Genome SNP Genotyping Arrays. Methods in Molecular Biology, 2013, 973, 355-372.	0.4	6
191	Criteria for Inference of Chromothripsis in Cancer Genomes. Cell, 2013, 152, 1226-1236.	13.5	457
192	Whole genome profiling and other high throughput technologies in lymphoid neoplasmsâ€"current contributions and future hopes. Modern Pathology, 2013, 26, S97-S110.	2.9	17
193	An Î±â€Ÿâ€catenin (<scp>CTNNA1</scp>) mutation in hereditary diffuse gastric cancer. Journal of Pathology, 2013, 229, 621-629.	2.1	184
194	Establishment of tumorâ€specific copy number alterations from plasma DNA of patients with cancer. International Journal of Cancer, 2013, 133, 346-356.	2.3	155
195	Two algorithms for biospecimen comparison and differentiation using SNP genotypes. Pharmacogenomics, 2013, 14, 379-390.	0.6	4
196	Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. Oncogene, 2013, 32, 2715-2725.	2.6	39
197	Identification of eight candidate target genes of the recurrent 3p12â€"p14 loss in cervical cancer by integrative genomic profiling. Journal of Pathology, 2013, 230, 59-69.	2.1	37
198	Genetic instability of the tumor suppressor gene FHIT in normal human cells. Genes Chromosomes and Cancer, 2013, 52, 832-844.	1.5	12
199	The cellular etiology of chromosome translocations. Current Opinion in Cell Biology, 2013, 25, 357-364.	2.6	34
200	A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response. Oncogene, 2013, 32, 3577-3586.	2.6	35
201	Network biomarkers reveal dysfunctional gene regulations during disease progression. FEBS Journal, 2013, 280, 5682-5695.	2.2	70
202	Estimating Selection Coefficients in Spatially Structured Populations from Time Series Data of Allele Frequencies. Genetics, 2013, 193, 973-984.	1.2	115
203	An algorithmic approach for breakage-fusion-bridge detection in tumor genomes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5546-5551.	3.3	53

#	Article	IF	Citations
204	DNA Double-Strand Breaks Coupled with PARP1 and HNRNPA2B1 Binding Sites Flank Coordinately Expressed Domains in Human Chromosomes. PLoS Genetics, 2013, 9, e1003429.	1.5	29
205	Fragile Site Instability in Saccharomyces cerevisiae Causes Loss of Heterozygosity by Mitotic Crossovers and Break-Induced Replication. PLoS Genetics, 2013, 9, e1003817.	1.5	15
206	Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types. PLoS Genetics, 2013, 9, e1003464.	1.5	97
207	Chromothripsis and Focal Copy Number Alterations Determine Poor Outcome in Malignant Melanoma. Cancer Research, 2013, 73, 1454-1460.	0.4	86
208	Direct Measurements of Human Colon Crypt Stem Cell Niche Genetic Fidelity: The Role of Chance in Non-Darwinian Mutation Selection. Frontiers in Oncology, 2013, 3, 264.	1.3	24
209	Role of DNA secondary structures in fragile site breakage along human chromosome 10. Human Molecular Genetics, 2013, 22, 1443-1456.	1.4	41
210	Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. Human Molecular Genetics, 2013, 22, 1735-1745.	1.4	13
211	Warburg effect and translocation-induced genomic instability: two yeast models for cancer cells. Frontiers in Oncology, 2012, 2, 212.	1.3	21
212	Precise inference of copy number alterations in tumor samples from SNP arrays. Bioinformatics, 2013, 29, 2964-2970.	1.8	12
213	Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. International Journal of Cancer, 2013, 132, 2020-2031.	2.3	32
214	A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Molecular Systems Biology, 2013, 9, 696.	3.2	90
215	Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B lossâ€induced global genome instability. Genes Chromosomes and Cancer, 2013, 52, 1017-1029.	1.5	54
216	Inference of Tumor Phylogenies with Improved Somatic Mutation Discovery. Journal of Computational Biology, 2013, 20, 933-944.	0.8	45
217	Portrait of replication stress viewed from telomeres. Cancer Science, 2013, 104, 790-794.	1.7	14
218	Genome evolution during progression to breast cancer. Genome Research, 2013, 23, 1097-1108.	2.4	98
219	Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. Oncogene, 2013, 32, 171-179.	2.6	57
220	Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1999-2004.	3.3	348
221	DNA synthesis by Pol Î· promotes fragile site stability by preventing under-replicated DNA in mitosis. Journal of Cell Biology, 2013, 201, 395-408.	2.3	165

#	Article	IF	Citations
222	Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites. Scientific Reports, 2013, 3, 2189.	1.6	7
223	A decision-theoretic approach for segmental classification. Annals of Applied Statistics, 2013, 7, .	0.5	11
224	High-expression of DJ-1 and Loss of PTEN Associated with Tumor Metastasis and Correlated with Poor Prognosis of Gastric Carcinoma. International Journal of Medical Sciences, 2013, 10, 1689-1697.	1.1	37
225	Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Experimental and Therapeutic Medicine, 2013, 5, 57-64.	0.8	27
226	Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS ONE, 2013, 8, e66264.	1.1	34
227	Cancer Genes and Chromosome Instability. , 0, , .		4
228	Integrated Analysis of Whole Genome and Transcriptome Sequencing Reveals Diverse Transcriptomic Aberrations Driven by Somatic Genomic Changes in Liver Cancers. PLoS ONE, 2014, 9, e114263.	1.1	79
229	Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Advances in Medicine, 2014, 2014, 1-25.	0.3	31
230	Role of common fragile sites and corresponding genes in cancer development. Cellular and Molecular Life Sciences, 2014, 71, 4487-4488.	2.4	9
231	Are common fragile sites merely structural domains or highly organized â€œfunctionalâ€•units susceptible to oncogenic stress?. Cellular and Molecular Life Sciences, 2014, 71, 4519-4544.	2.4	52
232	Targeting Oncogenic Drivers. Progress in Tumor Research, 2014, 41, 1-14.	0.1	7
233	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics and Personalized Medicine, 2014, 7, 203.	0.4	83
234	Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis. Cancers, 2014, 6, 1208-1219.	1.7	23
235	ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress. DNA Repair, 2014, 24, 122-130.	1.3	26
236	Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. Pharmacogenomics, 2014, 15, 1943-1946.	0.6	5
237	seqCNA: an R package for DNA copy number analysis in cancer using high-throughput sequencing. BMC Genomics, 2014, 15, 178.	1.2	11
238	Molecular characterization of common fragile sites as a strategy to discover cancer susceptibility genes. Cellular and Molecular Life Sciences, 2014, 71, 4561-4575.	2.4	18
239	MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17606-17611.	3.3	56

#	Article	IF	Citations
240	Quantitative Analysis of Single Amino Acid Variant Peptides Associated with Pancreatic Cancer in Serum by an Isobaric Labeling Quantitative Method. Journal of Proteome Research, 2014, 13, 6058-6066.	1.8	26
241	High CD49f expression is associated with osteosarcoma tumor progression: a study using patientâ€derived primary cell cultures. Cancer Medicine, 2014, 3, 796-811.	1.3	15
242	WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4716-25.	3.3	77
243	CLImAT: accurate detection of copy number alteration and loss of heterozygosity in impure and aneuploid tumor samples using whole-genome sequencing data. Bioinformatics, 2014, 30, 2576-2583.	1.8	43
244	New concepts in breast cancer genomics and genetics. Breast Cancer Research, 2014, 16, 460.	2.2	28
245	Updating the mechanisms of common fragile site instability: how to reconcile the different views?. Cellular and Molecular Life Sciences, 2014, 71, 4489-4494.	2.4	49
246	The common fragile site FRA16D gene product WWOX: roles in tumor suppression and genomic stability. Cellular and Molecular Life Sciences, 2014, 71, 4589-4599.	2.4	37
247	Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics, 2014, 30, i617-i623.	1.8	36
248	The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion. Human Molecular Genetics, 2014, 23, 5243-5250.	1.4	31
249	Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery. Epigenetics, 2014, 9, 75-80.	1.3	29
250	Comprehensive study of tumour single nucleotide polymorphism array data reveals significant driver aberrations and disrupted signalling pathways in human hepatocellular cancer. IET Systems Biology, 2014, 8, 24-32.	0.8	1
251	The early manifestation, tumor-specific occurrence and prognostic significance of TGFBR2 aberrant splicing in oral carcinoma. Experimental Cell Research, 2014, 327, 156-162.	1.2	11
252	Signaling through cyclin D-dependent kinases. Oncogene, 2014, 33, 1890-1903.	2.6	251
253	Allelic Imbalance at an 8q24 Oncogenic SNP is Involved in Activating MYC in Human Colorectal Cancer. Annals of Surgical Oncology, 2014, 21, 515-521.	0.7	11
254	Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment. Human Mutation, 2014, 35, 756-765.	1.1	170
255	Mechanisms of chromosomal instability in melanoma. Environmental and Molecular Mutagenesis, 2014, 55, 457-471.	0.9	16
256	Molecular Testing in Cancer. , 2014, , .		2
257	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics, 2014, 46, 588-594.	9.4	144

#	Article	IF	Citations
258	The evolution of the unstable cancer genome. Current Opinion in Genetics and Development, 2014, 24, 61-67.	1.5	62
259	The promise of whole-exome sequencing in medical genetics. Journal of Human Genetics, 2014, 59, 5-15.	1.1	404
260	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Experimental Hematology, 2014, 42, 927-938.	0.2	15
261	Copy number variants are produced in response to lowâ€dose ionizing radiation in cultured cells. Environmental and Molecular Mutagenesis, 2014, 55, 103-113.	0.9	41
262	Interplay between genetic and epigenetic factors governs common fragile site instability in cancer. Cellular and Molecular Life Sciences, 2014, 71, 4495-4506.	2.4	26
263	A role for DNA polymerase Î¸ in the timing of DNA replication. Nature Communications, 2014, 5, 4285.	5.8	73
264	Focal chromosomal copy number aberrations in cancerâ€"Needles in a genome haystack. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2698-2704.	1.9	55
265	WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 188-200.	3.3	89
266	Cancer: Evolution Within a Lifetime. Annual Review of Genetics, 2014, 48, 215-236.	3.2	196
267	Expanding the computational toolbox for mining cancer genomes. Nature Reviews Genetics, 2014, 15, 556-570.	7.7	166
268	CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. Cancer Research, 2014, 74, 3947-3958.	0.4	107
269	Cancer gene discovery goes mobile. Nature Genetics, 2014, 46, 928-929.	9.4	1
270	RPA Inhibition Increases Replication Stress and Suppresses Tumor Growth. Cancer Research, 2014, 74, 5165-5172.	0.4	51
271	RNA switch at enhancers. Nature Genetics, 2014, 46, 929-931.	9.4	4
272	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics, 2014, 46, 844-849.	9.4	208
273	Next-generation sequencing and DNA replication in human cells: the future has arrived. Future Oncology, 2014, 10, 683-693.	1.1	6
274	Downregulation of p16ink4a inhibits cell proliferation and induces G1 cell cycle arrest in cervical cancer cells. International Journal of Molecular Medicine, 2014, 33, 1577-1585.	1.8	12
275	Development of Multi-Null-Hypotheses Method for Detection of Selective Forces at Molecular Level in Evolution of Human Genes involved in DNA-Repair Mechanism Impaired in Cancer Progression. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2014, 47, 11547-11552.	0.4	0

#	Article	IF	Citations
276	Zielgerichtetes Vorgehen gegen onkogene Faktoren. Karger Kompass Onkologie, 2015, 2, 61-70.	0.0	0
277	Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme. Nucleic Acids Research, 2015, 43, 9340-9349.	6.5	28
278	Replication Stress and Telomere Dysfunction Are Present in Cultured Human Embryonic Stem Cells. Cytogenetic and Genome Research, 2015, 146, 251-260.	0.6	3
279	Current questions and controversies in chromosome fragile site research: does WWOX, the gene product of common fragile site FRA16D, have a passive or active role in cancer?. Cell Death Discovery, 2015, 1, 15040.	2.0	2
280	Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes and Cancer, 2015, 54, 472-481.	1.5	9
281	Can Petoâ€™s paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. BMC Cancer, 2015, 15, 792.	1.1	17
282	mRNA-Producing Pseudo-nucleus System. Small, 2015, 11, 5515-5519.	5.2	2
283	Tumor suppressor <scp>WWOX</scp> moderates the mitochondrial respiratory complex. Genes Chromosomes and Cancer, 2015, 54, 745-761.	1.5	30
284	Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptorâ€“induced epithelialâ€•mesenchymal transition. Hepatology, 2015, 62, 1201-1214.	3.6	49
285	Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology. Microarrays (Basel, Switzerland), 2015, 4, 339-369.	1.4	18
286	Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster. PLoS ONE, 2015, 10, e0136356.	1.1	16
287	Oncogenes create a unique landscape of fragile sites. Nature Communications, 2015, 6, 7094.	5.8	72
288	Basic and Ancillary Techniques in Bone Pathology. , 2015, , 73-83.		0
289	Collateral Lethality: A New Therapeutic Strategy in Oncology. Trends in Cancer, 2015, 1, 161-173.	3.8	106
290	Bmi-1 is essential for the oncogenic potential in CD133+ human laryngeal cancer cells. Tumor Biology, 2015, 36, 8931-8942.	0.8	12
291	Common Chromosomal Fragile Sites and Cancer. , 2015, , 73-94.		0
292	Therapeutic targeting of tumor suppressor genes. Cancer, 2015, 121, 1357-1368.	2.0	132
293	â€˜Latent driversâ€™ expand the cancer mutational landscape. Current Opinion in Structural Biology, 2015, 32, 25-32.	2.6	68

#	Article	IF	Citations
294	DNA Replication Stress as a Hallmark of Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 425-448.	9.6	593
295	WWOX: A fragile tumor suppressor. Experimental Biology and Medicine, 2015, 240, 296-304.	1.1	55
296	Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments. Current Oncology Reports, 2015, 17, 15.	1.8	29
297	NKD1 marks intestinal and liver tumors linked to aberrant Wnt signaling. Cellular Signalling, 2015, 27, 245-256.	1.7	19
298	Forging a signature of in vivo senescence. Nature Reviews Cancer, 2015, 15, 397-408.	12.8	775
299	OMICS for Tumor Biomarker Research. Biomarkers in Disease, 2015, , 3-30.	0.0	3
300	Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations. PLoS Computational Biology, 2015, 11, e1004147.	1.5	59
301	Replication stress and cancer. Nature Reviews Cancer, 2015, 15, 276-289.	12.8	755
302	WWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation. Journal of Medical Genetics, 2015, 52, 61-70.	1.5	74
303	Molecular Biology of Retinoblastoma. Essentials in Ophthalmology, 2015, , 1-13.	0.0	0
304	WWOX, the chromosomal fragile site FRA16D spanning gene: Its role in metabolism and contribution to cancer. Experimental Biology and Medicine, 2015, 240, 338-344.	1.1	29
305	The challenge of targeting metastasis. Cancer and Metastasis Reviews, 2015, 34, 635-641.	2.7	147
306	Reconstructing Breakage Fusion Bridge Architectures Using Noisy Copy Numbers. Journal of Computational Biology, 2015, 22, 577-594.	0.8	10
307	TopBP1 is required at mitosis to reduce transmission of DNA damage to G1 daughter cells. Journal of Cell Biology, 2015, 210, 565-582.	2.3	82
308	Patterns of somatic uniparental disomy identify novel tumor suppressor genes in colorectal cancer. Carcinogenesis, 2015, 36, 1103-1110.	1.3	18
309	A comprehensive transcriptional portrait of human cancer cell lines. Nature Biotechnology, 2015, 33, 306-312.	9.4	556
310	Large transcription units unify copy number variants and common fragile sites arising under replication stress. Genome Research, 2015, 25, 189-200.	2.4	152
311	Driver and Passenger Mutations in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 25-50.	9.6	291

#	Article	IF	Citations
312	Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. BMC Bioinformatics, 2016, 17, 222.	1.2	15
313	Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genetics, 2016, 12, e1006436.	1.5	34
314	The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma. Acta Dermato-Venereologica, 2016, 96, 3-16.	0.6	46
315	New paradigms in clonal evolution: punctuated equilibrium in cancer. Journal of Pathology, 2016, 240, 126-136.	2.1	69
316	Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry. Acta Cytologica, 2016, 60, 372-384.	0.7	19
317	Fragile Genes That Are Frequently Altered in Cancer: Players Not Passengers. Cytogenetic and Genome Research, 2016, 150, 208-216.	0.6	31
318	Chromosome Imbalances in Cancer: Molecular Cytogenetics Meets Genomics. Cytogenetic and Genome Research, 2016, 150, 176-184.	0.6	11
319	Fhit lossâ€associated initiation and progression of neoplasia in vitro. Cancer Science, 2016, 107, 1590-1598.	1.7	8
320	EZH2 orchestrates apicobasal polarity and neuroepithelial cell renewal. Neurogenesis (Austin, Tex), 2016, 3, e1250034.	1.5	11
321	CDK Inhibitors in Normal and Malignant Cells. , 2016, , 437-446.		1
322	Genomics of SCC: Tumor Formation, Progression, and Future Therapeutic Implications for High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , 67-102.		1
323	TopBP1 makes the final call for repair on the verge of cell division. Molecular and Cellular Oncology, 2016, 3, e1093066.	0.3	2
324	Translocation and deletion breakpoints in cancer genomes are associated with potential non-B DNA-forming sequences. Nucleic Acids Research, 2016, 44, 5673-5688.	6.5	117
325	Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nature Genetics, 2016, 48, 500-509.	9.4	596
326	High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , .		5
327	Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism. Cancer Cell, 2016, 29, 751-766.	7.7	145
328	The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process. Annual Review of Genetics, 2016, 50, 347-369.	3.2	86
329	Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. Endocrine-Related Cancer, 2016, 23, 635-650.	1.6	11

#	Article	IF	Citations
330	Importance of rare gene copy number alterations for personalized tumor characterization and survival analysis. Genome Biology, 2016, 17, 204.	3.8	19
331	Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing. ACS Nano, 2016, 10, 8705-8714.	7.3	22
332	Cancer-associated chromosomal deletions: Size makes a difference. Cell Cycle, 2016, 15, 2850-2851.	1.3	7
333	Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine. BMC Genomics, 2016, 17, 455.	1.2	7
334	Selectivity of ORC binding sites and the relation to replication timing, fragile sites, and deletions in cancers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4810-9.	3.3	164
335	The tumour suppressor CYLD regulates the p53 DNA damage response. Nature Communications, 2016, 7, 12508.	5.8	40
336	A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Reports, 2016, 17, 1193-1205.	2.9	556
337	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	5.8	1,221
338	Remarkably Long-Tract Gene Conversion Induced by Fragile Site Instability inSaccharomyces cerevisiae. Genetics, 2016, 204, 115-128.	1.2	11
339	Comprehensive Gene Mutation Profiling of Breast Tumors: Is It Ready for Prime Time Use?. Current Breast Cancer Reports, 2016, 8, 53-59.	0.5	0
340	Systematic analysis of somatic mutations driving cancer: uncovering functional protein regions in disease development. Biology Direct, 2016, 11, 23.	1.9	15
341	The complex nature of fragile site plasticity and its importance in cancer. Current Opinion in Cell Biology, 2016, 40, 131-136.	2.6	56
342	Identification of DNA Methylationâ€“Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma. Cancer Research, 2016, 76, 1954-1964.	0.4	28
343	Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nature Genetics, 2016, 48, 176-182.	9.4	283
344	DNA replication stress and cancer: cause or cure?. Future Oncology, 2016, 12, 221-237.	1.1	33
345	Transcription as a Threat to Genome Integrity. Annual Review of Biochemistry, 2016, 85, 291-317.	5.0	145
346	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 283-312.	9.6	106
347	Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression. Trends in Pharmacological Sciences, 2016, 37, 101-113.	4.0	75

#	Article	IF	Citations
348	Analysis of Structural Chromosome Variants by Next Generation Sequencing Methods. , 2016, , 39-61.		0
349	CDK6â€"a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 2016, 35, 3083-3091.	2.6	137
350	To break or not to break â€“ context matters. Molecular and Cellular Oncology, 2016, 3, e1072657.	0.3	1
351	Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process. Journal of Mathematical Biology, 2016, 72, 47-86.	0.8	12
352	Contribution of canonical nonhomologous end joining to chromosomal rearrangements is enhanced by ATM kinase deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 728-733.	3.3	28
353	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. Clinical Chemistry, 2017, 63, 532-541.	1.5	81
354	Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines. Endocrine-Related Cancer, 2017, 24, 209-220.	1.6	19
355	Rescue from replication stress during mitosis. Cell Cycle, 2017, 16, 613-633.	1.3	51
356	Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy. Scientific Reports, 2017, 7, 42060.	1.6	32
357	International cancer seminars: a focus on esophageal squamous cell carcinoma. Annals of Oncology, 2017, 28, 2086-2093.	0.6	149
358	A Direct Test of Selection in Cell Populations Using the Diversity in Gene Expression within Tumors. Molecular Biology and Evolution, 2017, 34, 1730-1742.	3.5	9
360	Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia, 2017, 19, 75-83.	2.3	27
361	Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue. International Journal of Cancer, 2017, 140, 1324-1330.	2.3	19
362	Chromosomal instability analysis and regional tumor heterogeneity in colon cancer. Cancer Genetics, 2017, 210, 9-21.	0.2	21
363	Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. Nature Communications, 2017, 8, 1221.	5.8	75
364	Sweepstake evolution revealed by population-genetic analysis of copy-number alterations in single genomes of breast cancer. Royal Society Open Science, 2017, 4, 171060.	1.1	20
365	Long non-coding RNAs: The novel diagnostic biomarkers for leukemia. Environmental Toxicology and Pharmacology, 2017, 55, 81-86.	2.0	22
366	Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins. Science Signaling, 2017, 10, .	1.6	54

#	Article	IF	Citations
367	Fragile sites in cancer: more than meets the eye. Nature Reviews Cancer, 2017, 17, 489-501.	12.8	187
368	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Targeted Oncology, 2017, 12, 571-597.	1.7	135
369	Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival. Npj Precision Oncology, 2017, 1, 9.	2.3	7
370	Transcription-replication conflicts at chromosomal fragile sitesâ€"consequences in M phase and beyond. Chromosoma, 2017, 126, 213-222.	1.0	17
371	Fhit and Wwox loss-associated genome instability: A genome caretaker one-two punch. Advances in Biological Regulation, 2017, 63, 167-176.	1.4	13
372	Wwoxâ€“Brca1 interaction: role in DNA repair pathway choice. Oncogene, 2017, 36, 2215-2227.	2.6	50
373	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	9.4	326
374	Common fragile sites (CFS) and extremely large CFS genes are targets for human papillomavirus integrations and chromosome rearrangements in oropharyngeal squamous cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 59-74.	1.5	40
375	Cyclin E Deregulation and Genomic Instability. Advances in Experimental Medicine and Biology, 2017, 1042, 527-547.	0.8	38
376	Coordinating Replication with Transcription. Advances in Experimental Medicine and Biology, 2017, 1042, 455-487.	0.8	12
377	Functions and Epigenetic Regulation of Wwox in Bone Metastasis from Breast Carcinoma: Comparison with Primary Tumors. International Journal of Molecular Sciences, 2017, 18, 75.	1.8	17
378	Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncology Letters, 2017, 14, 4372-4378.	0.8	9
379	InÂVitro Models of HCC. , 2017, , 563-579.		1
380	The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis. Biology, 2017, 6, 12.	1.3	118
381	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	1.8	353
382	Oncogene-Induced Replication Stress Drives Genome Instability and Tumorigenesis. International Journal of Molecular Sciences, 2017, 18, 1339.	1.8	18
383	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PLoS ONE, 2017, 12, e0176045.	1.1	28
384	Accurate prediction of functional effects for variants by combining gradient tree boosting with optimal neighborhood properties. PLoS ONE, 2017, 12, e0179314.	1.1	43

#	Article	IF	Citations
385	Impact of FHIT loss on the translation of cancer-associated mRNAs. Molecular Cancer, 2017, 16, 179.	7.9	20
386	QuaDMutEx: quadratic driver mutation explorer. BMC Bioinformatics, 2017, 18, 458.	1.2	8
387	Brain tumor initiating cells: with great technology will come greater understanding. Future Neurology, 2017, 12, 223-236.	0.9	1
388	Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget, 2017, 8, 50252-50272.	0.8	50
389	Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature, 2018, 555, 112-116.	13.7	303
390	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. Clinical Cancer Research, 2018, 24, 3299-3308.	3.2	37
391	Replication stress induces accumulation of FANCD2 at central region of large fragile genes. Nucleic Acids Research, 2018, 46, 2932-2944.	6.5	70
392	FANCD2 binding identifies conserved fragile sites at large transcribed genes in avian cells. Nucleic Acids Research, 2018, 46, 1280-1294.	6.5	43
393	Evaluation of NCI-7 Cell Line Panel as a Reference Material for Clinical Proteomics. Journal of Proteome Research, 2018, 17, 2205-2215.	1.8	17
394	Pathways for maintenance of telomeres and common fragile sites during DNA replication stress. Open Biology, 2018, 8, 180018.	1.5	61
395	Chromatin reprogramming in breast cancer. Endocrine-Related Cancer, 2018, 25, R385-R404.	1.6	17
396	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
397	Association of CDKN2A/CDKN2B with inflammatory bowel disease in Koreans. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 887-893.	1.4	7
398	DNA replication stress drives fragile site instability. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 808, 56-61.	0.4	19
399	CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A. Oncogene, 2018, 37, 128-138.	2.6	44
400	BLM prevents instability of structure-forming DNA sequences at common fragile sites. PLoS Genetics, 2018, 14, e1007816.	1.5	25
401	Integrated Modeling of GC-Content, Mappability, Tumor Impurity and Aneuploidy for Accurate Detection of Genomic Aberrations. IEEE Access, 2018, 6, 64096-64106.	2.6	0
402	Common Chromosomal Fragile Sitesâ€"Conserved Failure Stories. Genes, 2018, 9, 580.	1.0	17

#	Article	IF	Citations
403	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2018, 9, 5235.	5.8	118
404	Detours to Replication: Functions of Specialized DNA Polymerases during Oncogene-induced Replication Stress. International Journal of Molecular Sciences, 2018, 19, 3255.	1.8	27
405	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery, 2018, 8, 1404-1421.	7.7	311
406	An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Scientific Reports, 2018, 8, 13537.	1.6	49
407	Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. Nature Communications, 2018, 9, 2054.	5.8	68
408	Î±Eâ€catenin is a candidate tumor suppressor for the development of Eâ€cadherinâ€expressing lobularâ€type breast cancer. Journal of Pathology, 2018, 245, 456-467.	2.1	34
409	The DNA Damage Response: Roles in Cancer Etiology and Treatment. Cancer Drug Discovery and Development, 2018, , 11-33.	0.2	2
410	The Role of Chromosome Deletions in Human Cancers. Advances in Experimental Medicine and Biology, 2018, 1044, 135-148.	0.8	10
412	Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer. International Journal of Molecular Sciences, 2018, 19, 570.	1.8	129
413	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
414	Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis. International Journal of Molecular Sciences, 2018, 19, 2191.	1.8	10
415	A Nexus model of cellular transition in cancer. Biological Research, 2018, 51, 23.	1.5	1
416	Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer. Cell Death and Disease, 2018, 9, 832.	2.7	26
417	Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion. Emerging Microbes and Infections, 2018, 7, 1-12.	3.0	22
418	Wwox Deletion in Mouse B Cells Leads to Genomic Instability, Neoplastic Transformation, and Monoclonal Gammopathies. Frontiers in Oncology, 2019, 9, 517.	1.3	4
419	ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma. Cancer Research, 2019, 79, 5159-5166.	0.4	10
420	The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules, 2019, 9, 713.	1.8	17
421	Variational Autoencoders for Cancer Data Integration: Design Principles and Computational Practice. Frontiers in Genetics, 2019, 10, 1205.	1.1	76

#	Article	IF	Citations
422	Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. Frontiers in Oncology, 2018, 8, 658.	1.3	21
423	Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Frontiers in Immunology, 2019, 10, 1113.	2.2	128
424	Fibroblast Growth Factor Receptor Signaling in Skin Cancers. Cells, 2019, 8, 540.	1.8	49
425	Frequent homozygous deletions of the CDKN2A locus in somatic cancer tissues. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2019, 815, 30-40.	0.4	11
426	Sequence and Nuclease Requirements for Breakage and Healing of a Structure-Forming (AT)n Sequence within Fragile Site FRA16D. Cell Reports, 2019, 27, 1151-1164.e5.	2.9	33
427	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell, 2019, 35, 441-456.e8.	7.7	82
428	Intracellular pH dynamics and charge-changing somatic mutations in cancer. Cancer and Metastasis Reviews, 2019, 38, 17-24.	2.7	19
429	Mechanisms of PTEN loss in cancer: Itâ€™s all about diversity. Seminars in Cancer Biology, 2019, 59, 66-79.	4.3	214
430	Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. Scientific Reports, 2019, 9, 1482.	1.6	25
431	Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C. Blood Advances, 2019, 3, 21-32.	2.5	20
432	Genomic instability in fragile sitesâ€”still adding the pieces. Genes Chromosomes and Cancer, 2019, 58, 295-304.	1.5	15
433	The FRA14B common fragile site maps to a region prone to somatic and germline rearrangements within the large GPHN gene. Genes Chromosomes and Cancer, 2019, 58, 284-294.	1.5	5
434	Genome-wide mapping of 8-oxo-7,8-dihydro-2â€²-deoxyguanosine reveals accumulation of oxidatively-generated damage at DNA replication origins within transcribed long genes of mammalian cells. Nucleic Acids Research, 2019, 47, 221-236.	6.5	94
435	Precision medicine review: rare driver mutations and their biophysical classification. Biophysical Reviews, 2019, 11, 5-19.	1.5	43
436	Differentiated super-enhancers in lung cancer cells. Science China Life Sciences, 2019, 62, 1218-1228.	2.3	2
437	Immunotherapy in pancreatic cancer: New hope or mission impossible?. Cancer Letters, 2019, 445, 57-64.	3.2	26
438	Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers. International Journal of Cancer, 2019, 144, 513-524.	2.3	6
439	WWOX, the FRA16D gene: A target of and a contributor to genomic instability. Genes Chromosomes and Cancer, 2019, 58, 324-338.	1.5	28

#	Article	IF	Citations
440	Common fragile site instability in normal cells: Lessons and perspectives. Genes Chromosomes and Cancer, 2019, 58, 260-269.	1.5	4
441	The role of fork stalling and DNA structures in causing chromosome fragility. Genes Chromosomes and Cancer, 2019, 58, 270-283.	1.5	62
442	Mechanisms shaping the mutational landscape of the FRA3B/FHITâ€deficient cancer genome. Genes Chromosomes and Cancer, 2019, 58, 317-323.	1.5	12
443	Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation. Cellular and Molecular Life Sciences, 2020, 77, 2605-2620.	2.4	10
444	Nucleic Acid Detection and Structural Investigations. Methods in Molecular Biology, 2020, , .	0.4	1
445	Inferring Tumor Proliferative Organization from Phylogenetic Tree Measures in a Computational Model. Systematic Biology, 2020, 69, 623-637.	2.7	13
446	The canonical non-homologous end joining factor XLF promotes chromosomal deletion rearrangements in human cells. Journal of Biological Chemistry, 2020, 295, 125-137.	1.6	12
447	The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129722.	1.1	4
448	Common Fragile Sites Are Characterized by Faulty Condensin Loading after Replication Stress. Cell Reports, 2020, 32, 108177.	2.9	33
449	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell, 2020, 183, 197-210.e32.	13.5	141
450	3D genome organization contributes to genome instability at fragile sites. Nature Communications, 2020, 11, 3613.	5.8	46
451	Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion. Oncogene, 2020, 39, 5690-5707.	2.6	7
452	In vitro anticancer activity of Eclipta alba whole plant extract on colon cancer cell HCT-116. BMC Complementary Medicine and Therapies, 2020, 20, 355.	1.2	37
453	Germline genomic patterns are associated with cancer risk, oncogenic pathways, and clinical outcomes. Science Advances, 2020, 6, .	4.7	12
454	Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Communications Biology, 2020, 3, 724.	2.0	5
455	Genomic instability and cancer: lessons from Drosophila. Open Biology, 2020, 10, 200060.	1.5	12
456	AmpliconReconstructor integrates NGS and optical mapping to resolve the complex structures of focal amplifications. Nature Communications, 2020, 11, 4374.	5.8	49
457	The impact of transcription-mediated replication stress on genome instability and human disease. Genome Instability & Disease, 2020, 1, 207-234.	0.5	8

#	Article	IF	Citations
458	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. Journal of Clinical Medicine, 2020, 9, 2690.	1.0	18
459	Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature Cancer, 2020, 1, 923-934.	5.7	67
460	H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival. Journal of Clinical Medicine, 2020, 9, 2844.	1.0	10
461	Genome-wide detection of tandem DNA repeats that are expanded in autism. Nature, 2020, 586, 80-86.	13.7	155
462	gpps: an ILP-based approach for inferring cancer progression with mutation losses from single cell data. BMC Bioinformatics, 2020, 21, 413.	1.2	10
463	Interleukin-12 elicits a non-canonical response in B16 melanoma cells to enhance survival. Cell Communication and Signaling, 2020, 18, 78.	2.7	4
464	High-resolution mapping of mitotic DNA synthesis regions and common fragile sites in the human genome through direct sequencing. Cell Research, 2020, 30, 997-1008.	5.7	74
465	QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency. BMC Bioinformatics, 2020, 21, 122.	1.2	8
466	Common fragile sites: protection and repair. Cell and Bioscience, 2020, 10, 29.	2.1	29
467	Analyses of non-coding somatic drivers in 2,658Âcancer whole genomes. Nature, 2020, 578, 102-111.	13.7	424
468	A distinct role for recombination repair factors in an early cellular response to transcriptionâ€“replication conflicts. Nucleic Acids Research, 2020, 48, 5467-5484.	6.5	23
469	Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes. BMC Bioinformatics, 2020, 21, 147.	1.2	8
470	The role of long nonâ€coding <scp>RNAs</scp> and downstream signaling pathways in leukemia progression. Hematological Oncology, 2021, 39, 27-40.	0.8	8
471	Computational and systems biology of cancer. Computational and Systems Oncology, 2021, 1, e1005.	1.1	0
472	MPL resolves genetic linkage in fitness inference from complex evolutionary histories. Nature Biotechnology, 2021, 39, 472-479.	9.4	26
473	Comprehensive Assessment of Copy Number Alterations Uncovers Recurrent AIFM3 and DLK1 Copy Gain in Medullary Thyroid Carcinoma. Cancers, 2021, 13, 218.	1.7	7
474	PathMEx: Pathway-Based Mutual Exclusivity for Discovering Rare Cancer Driver Mutations. Lecture Notes in Computer Science, 2021, , 564-577.	1.0	0
475	NRG1 fusions in breast cancer. Breast Cancer Research, 2021, 23, 3.	2.2	18

#	Article	IF	Citations
476	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
477	Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer. Frontiers in Oncology, 2021, 11, 621060.	1.3	11
478	Prostate Carcinogenesis: Insights in Relation to Epigenetics and Inflammation. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 253-267.	0.6	11
479	Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution. Cancers, 2021, 13, 1380.	1.7	38
482	Breaking the paradigm: early insights from mammalian DNA breakomes. FEBS Journal, 2022, 289, 2409-2428.	2.2	3
483	Cytolethal Distending Toxin Promotes Replicative Stress Leading to Genetic Instability Transmitted to Daughter Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 656795.	1.8	8
484	Signatures of Discriminative Copy Number Aberrations in 31 Cancer Subtypes. Frontiers in Genetics, 2021, 12, 654887.	1.1	6
485	WWOX Loses the Ability to Regulate Oncogenic AP-2Î³ and Synergizes with Tumor Suppressor AP-2Î± in High-Grade Bladder Cancer. Cancers, 2021, 13, 2957.	1.7	8
486	Locus-specific transcription silencing at the FHIT gene suppresses replication stress-induced copy number variant formation and associated replication delay. Nucleic Acids Research, 2021, 49, 7507-7524.	6.5	16
487	Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene. Life Science Alliance, 2021, 4, e202101019.	1.3	2
490	Large Intronic Deletion of the Fragile Site Gene PRKN Dramatically Lowers Its Fragility Without Impacting Gene Expression. Frontiers in Genetics, 2021, 12, 695172.	1.1	2
491	Targeting RB1 Loss in Cancers. Cancers, 2021, 13, 3737.	1.7	24
494	Copy number alterations identify a smoking-associated expression signature predictive of poor outcome in head and neck squamous cell carcinoma. Cancer Genetics, 2021, 256-257, 136-148.	0.2	1
496	PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. Theranostics, 2021, 11, 3742-3759.	4.6	30
498	Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods in Molecular Biology, 2020, 2063, 207-234.	0.4	8
499	Integrating â€œOmicsâ€•Data for Quantitative and Systems Pharmacology in Translational Oncology. , 2013, , 187-206.		1
500	Reconstructing Breakage Fusion Bridge Architectures Using Noisy Copy Numbers. Lecture Notes in Computer Science, 2014, , 400-417.	1.0	1
501	Inference of Tumor Phylogenies with Improved Somatic Mutation Discovery. Lecture Notes in Computer Science, 2013, , 249-263.	1.0	2

#	Article	IF	Citations
502	Spindle Assembly Checkpoint: Its Control and Aberration. , 2016, , 429-447.		1
511	Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. Journal of Clinical Investigation, 2013, 123, 2169-2182.	3.9	36
512	Proteomic Changes Resulting from Gene Copy Number Variations in Cancer Cells. PLoS Genetics, 2010, 6, e1001090.	1.5	126
513	FOXM1 Induces a Global Methylation Signature That Mimics the Cancer Epigenome in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2012, 7, e34329.	1.1	68
514	Somatic Mutations, Allele Loss, and DNA Methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) Gene Reveals Association with Early Age of Diagnosis in Colorectal Cancer Patients. PLoS ONE, 2013, 8, e58731.	1.1	30
515	The Relative Timing of Mutations in a Breast Cancer Genome. PLoS ONE, 2013, 8, e64991.	1.1	22
516	Loss of Heterozygosity and Copy Number Alterations in Flow-Sorted Bulky Cervical Cancer. PLoS ONE, 2013, 8, e67414.	1.1	7
517	DNA Topoisomerases Participate in Fragility of the Oncogene RET. PLoS ONE, 2013, 8, e75741.	1.1	24
518	Fhit Deficiency-Induced Global Genome Instability Promotes Mutation and Clonal Expansion. PLoS ONE, 2013, 8, e80730.	1.1	27
519	Genome-Wide Identification of Somatic Aberrations from Paired Normal-Tumor Samples. PLoS ONE, 2014, 9, e87212.	1.1	8
520	Molecular Integrative Clustering of Asian Gastric Cell Lines Revealed Two Distinct Chemosensitivity Clusters. PLoS ONE, 2014, 9, e111146.	1.1	2
521	Modeling the dynamics of chromosomal alteration progression in cervical cancer: A computational model. PLoS ONE, 2017, 12, e0180882.	1.1	2
522	Prominent features of the amino acid mutation landscape in cancer. PLoS ONE, 2017, 12, e0183273.	1.1	26
523	DNA replication stress: oncogenes in the spotlight. Genetics and Molecular Biology, 2020, 43, e20190138.	0.6	36
524	DNA replication stress: oncogenes in the spotlight. Genetics and Molecular Biology, 2020, 43, e20190138.	0.6	40
525	Practical clues for diagnosing WWOX encephalopathy. Epileptic Disorders, 2017, 19, 357-361.	0.7	11
526	Polymorphisms in DNA repair genes XRCC2 and XRCC3 risk of gastric cancer in Turkey. Bosnian Journal of Basic Medical Sciences, 2014, 14, 214-218.	0.6	12
527	FAM190A Rearrangements Provide a Multitude of Individualized Tumor Signatures and Neo-antigens in Cancer. Oncotarget, 2011, 2, 69-75.	0.8	11

#	Article	IF	Citations
528	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. Oncotarget, 2018, 9, 23960-23974.	0.8	13
529	The rabbit as an orthologous small animal model for APOBEC3A oncogenesis. Oncotarget, 2018, 9, 27809-27822.	0.8	3
530	WWOX modulates the ATR-mediated DNA damage checkpoint response. Oncotarget, 2016, 7, 4344-4355.	0.8	54
531	In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. Oncotarget, 2016, 7, 2780-2795.	0.8	20
532	Mapping of deletion breakpoints at theCDKN2Alocus in melanoma: detection ofMTAP-ANRILfusion transcripts. Oncotarget, 2016, 7, 16490-16504.	0.8	22
533	Homeobox protein VentX induces p53-independent apoptosis in cancer cells. Oncotarget, 2016, 7, 39719-39729.	0.8	11
534	Evolving insights: how DNA repair pathways impact cancer evolution. Cancer Biology and Medicine, 2020, 17, 805-827.	1.4	17
535	Chromothripsis in Oncology: Literature Review and Case Report. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 191-205.	0.1	4
536	3D Culture Modelling: An Emerging Approach for Translational Cancer Research in Sarcomas. Current Medicinal Chemistry, 2020, 27, 4778-4788.	1.2	6
537	Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies. World Journal of Stem Cells, 2016, 8, 170.	1.3	14
538	Genome-wide integrative analysis revealed a correlation between lengths of copy number segments and corresponding gene expression profile. Bioinformation, 2011, 7, 280-284.	0.2	3
539	Cell Lines, Tissue Samples, Model Organisms, and Biobanks: Infrastructure and Tools for Cancer Systems Biology. , 2011, , 127-152.		1
540	Somatic Copy Number Alterations: Gene and Protein Expression Correlates in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. , 2012, , 405-428.		0
541	Transcriptomic Analysis of Human Ovarian Cancer Cells: Changes Mediated by Luteinizing Hormone Receptor Activation. , 0, , .		0
542	Molecular Diagnosis of Cancer. , 2014, , 249-346.		1
543	Microarray-Based Investigations in Cancer. , 2014, , 87-106.		0
544	Elucidation of Cancer Drivers Through Comparative Omic Data Analyses. , 2014, , 113-147.		0
545	OMICS for Tumor Biomarker Research. , 2014, , 1-22.		0

#	Article	IF	Citations
547	Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity. Current Proteomics, 2014, 11, 210-217.	0.1	1
557	Sequence and Nuclease Requirements for Breakage and Healing of a Structure-Forming (AT)n Sequence within Fragile Site FRA16D. SSRN Electronic Journal, 0, , .	0.4	0
565	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. Cancers, 2021, 13, 5396.	1.7	17
566	Mass spectrometryâ€based targeted proteomics for analysis of protein mutations. Mass Spectrometry Reviews, 2023, 42, 796-821.	2.8	19
570	The complexity of genome rearrangement combinatorics under the infinite sites model. Journal of Theoretical Biology, 2020, 501, 110335.	0.8	1
571	Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 3882-91.	0.5	42
572	DCMP: database of cancer mutant protein domains. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	0
573	Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability. Frontiers in Cell and Developmental Biology, 2021, 9, 774845.	1.8	57
574	CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer. International Journal of General Medicine, 2021, Volume 14, 8689-8710.	0.8	10
575	Integrated genome and transcriptome analyses reveal the mechanism of genome instability in ataxia with oculomotor apraxia 2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	16
576	GenomeTornadoPlot: a novel R package for CNV visualization and focality analysis. Bioinformatics, 2022, , .	1.8	0
577	Cancer Genomic Rearrangements and Copy Number Alterations from Errors in Cell Division. Annual Review of Cancer Biology, 2022, 6, 245-268.	2.3	10
578	Transcriptionâ€“Replication Coordination. Life, 2022, 12, 108.	1.1	2
579	Distribution of copy number variations and rearrangement endpoints in human cancers with a review of literature. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2022, 824, 111773.	0.4	6
580	Association between the copy number variation ofCCSER1gene and growth traits in ChineseCapra hircus(goat) populations. Animal Biotechnology, 2023, 34, 1377-1383.	0.7	6
581	Novel germline mutation in lung cancer pedigrees establishes BCAR1 as a human cancer susceptibility gene: a case report. Annals of Translational Medicine, 2022, 10, 237-237.	0.7	1
582	Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma. PLoS ONE, 2022, 17, e0245817.	1.1	2
584	A general calculus of fitness landscapes finds genes under selection in cancers. Genome Research, 2022, , gr.275811.121.	2.4	7

#	Article	IF	Citations
585	Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas. Communications Biology, 2022, 5, 335.	2.0	8
586	AU-Rich Element RNA Binding Proteins: At the Crossroads of Post-Transcriptional Regulation and Genome Integrity. International Journal of Molecular Sciences, 2022, 23, 96.	1.8	19
587	Enhanced Bayesian detection for copy number alterations from next-generation sequencing data. , 2021, , .		0
617	miRNAs Copy Number Variations Repertoire as Hallmark Indicator of Cancer Species Predisposition. Genes, 2022, 13, 1046.	1.0	5
620	Selective pericentromeric heterochromatin dismantling caused by TP53 activation during senescence. Nucleic Acids Research, 2022, 50, 7493-7510.	6.5	5
621	Methylation-mediated silencing of PTPRD induces pulmonary hypertension by promoting pulmonary arterial smooth muscle cell migration via the PDGFRB/PLCÎ³1 axis. Journal of Hypertension, 2022, 40, 1795-1807.	0.3	8
622	Novel insights into RB1 mutation. Cancer Letters, 2022, 547, 215870.	3.2	13
623	Cell Division/Death: Cell Cycle â€“ CDK Inhibitors in Normal and Malignant Cells. , 2022, , .		0
624	Processing DNA lesions during mitosis to prevent genomic instability. Biochemical Society Transactions, 2022, 50, 1105-1118.	1.6	3
626	Replication stress generates distinctive landscapes of DNA copy number alterations and chromosome scale losses. Genome Biology, 2022, 23, .	3.8	16
627	Fragile sites, chromosomal lesions, tandem repeats, and disease. Frontiers in Genetics, 0, 13, .	1.1	7
628	Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. Nature, 2022, 612, 495-502.	13.7	28
629	Identification of an Amino Acid Metabolism-Related Gene Signature for Predicting Prognosis in Lung Adenocarcinoma. Genes, 2022, 13, 2295.	1.0	1
631	Estimating linkage disequilibrium and selection from allele frequency trajectories. Genetics, 2023, 223, .	1.2	1
632	The role of serine metabolism in lung cancer: From oncogenesis to tumor treatment. Frontiers in Genetics, 0, 13, .	1.1	3
633	Piperineâ€“Chlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases. Pharmaceuticals, 2023, 16, 145.	1.7	5
635	Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models. Drug Resistance Updates, 2023, 68, 100956.	6.5	5
636	Co-dependent regulation of p-BRAF and potassium channel KCNMA1 levels drives glioma progression. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	2

#	Article	IF	Citations
637	A CRISPR-del-based pipeline for complete gene knockout in human diploid cells. Journal of Cell Science, 2023, 136, .	1.2	3
638	High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16, 63-81.	2.3	1
639	Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome. Scientific Reports, 2023, 13, .	1.6	5
643	Novel patterns of cancer genome evolution. , 2015, 1, 222-225.		0